NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$18.48 USD
-0.64 (-3.32%)
Updated Jul 18, 2024 04:00 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
NVCR 18.48 -0.64(-3.32%)
Will NVCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVCR
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
NVCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
Other News for NVCR
CereVasc Announces Appointments of New Directors
PROCEPT BioRobotics Corp's Meteoric Rise: Unpacking the 25% Surge in Just 3 Months
First Week of December 20th Options Trading For NovoCure (NVCR)
NovoCure Shareholders Elect Directors and Endorse Key Proposals
Stocks with the highest and lowest liquidity - Goldman Sachs